Mon, Dec 29, 2014, 6:53 AM EST - U.S. Markets open in 2 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Delcath Systems, Inc. Message Board

melikesdinero 25 posts  |  Last Activity: Dec 3, 2014 8:17 PM Member since: Apr 1, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CLSN

    by melikesdinero Dec 1, 2014 6:41 PM
    melikesdinero melikesdinero Dec 3, 2014 8:17 PM Flag

    Good call. Followed those guys closer before, then when they hit opposition abroad, I lost interest. Delcath is flying under the radar lately, but... Still watching developments in Germany / UK closely.

    Sentiment: Buy

  • melikesdinero by melikesdinero Dec 1, 2014 6:41 PM Flag

    Anyone following them anymore? Still invested over there Neal?

    Sentiment: Buy

  • Reply to

    Many ODAC safety issues not reported

    by who_gnu_1235 Nov 21, 2014 1:22 PM
    melikesdinero melikesdinero Nov 21, 2014 3:20 PM Flag

    CHEMOSAT®Hepatic Delivery System• Approved as Class IIb Medical Device; kit supplied w/o
    melphalan• Broad indication for intra-hepatic administration of
    melphalan hydrochloride and subsequent filtration of the
    venous blood return• 130 commercial procedures performed in 15 leading
    cancer centers in the EU• Reimbursement via Individual Funding Requests; NUB
    Value 4 Status in Germany• Growing Support for NUB Value 1 Status among
    German KOLs; 2015 NUB decision by February 1, 2015• UK Block Grants pending & private pay insurance

    Sentiment: Buy

  • Reply to

    Many ODAC safety issues not reported

    by who_gnu_1235 Nov 21, 2014 1:22 PM
    melikesdinero melikesdinero Nov 21, 2014 3:17 PM Flag

    Improved device and procedure since prior trials o 130 EU treatments o 20 treatments in US Expanded Access Program and
    Compassionate Use cases o Many issues raised at ODAC have not been reported• EU patients report improved QoL• Current device/procedure permitting multiple treatment cycles• Recent scientific presentations at ESSO for OM from 3 centers in
    US and EU o University Southampton reported 47% of patients had a partial
    response and 16% had a complete response o Moffitt reported 67% of patients had a partial response. In addition,
    one patient was reported to have a complete response o Leiden reported 80% of patients had a partial response

    Sentiment: Buy

  • Reply to

    Many ODAC safety issues not reported

    by who_gnu_1235 Nov 21, 2014 1:22 PM
    melikesdinero melikesdinero Nov 21, 2014 3:16 PM Flag

    16 DELCATH SYSTEMS, INCRisks Observed in Previous Clinical Trials• Risks observed using product and procedure protocol from Previous Clinical
    Program• Integrated safety population of patients showed risks associated with
    Melphalan/ HDS to include: o 4.1% incidence of deaths due to adverse reactions o 4% incidence of stroke o 2% reported incidence of myocardial infarction in the setting of an incomplete cardiac
    risk assessment o a ≥ 70% incidence of grade 4 bone marrow suppression with a median time of
    recovery of greater than 1 week o 18% incidence of febrile neutropenia, along with the additive risk of hepatic injury,
    severe hemorrhage, and gastrointestinal perforation o Deaths due to certain adverse reactions did not occur again during the
    clinical trials following the adoption of related protocol amendments o Reports from treating physicians in US and EU indicate improved safety
    profile with improved device and procedure refinements

    Sentiment: Buy

  • Reply to

    Many ODAC safety issues not reported

    by who_gnu_1235 Nov 21, 2014 1:22 PM
    melikesdinero melikesdinero Nov 21, 2014 3:12 PM Flag

    If you read them in a report, then they were reported =)

    Sentiment: Buy

  • Reply to

    future is not easy

    by samnotsamuel1 Nov 21, 2014 9:45 AM
    melikesdinero melikesdinero Nov 21, 2014 10:47 AM Flag

    Let's say, 26 years+

    Old Quote:

    "3 Things to Watch With Delcath Systems
    ARTICLE PREVIEW — For full access, register below, it's free
    By Sean Williams | More Articles
    September 19, 2012 | Comments (0)

    Delcath Systems (Nasdaq: DCTH ) is a specialty pharmaceutical and medical device company focused on oncological treatments.

    Today, let's look at three things investors should be watching regarding Delcath Systems, as they will provide us with better insight into the company.

    1. NDA filing for hepatic Chemosat therapy device with melphalan
    After waiting for 24 years (no joke, 24!), it appears that Delcath shareholders finally have a reason to be excited, with the company filing a new drug application with the Food and Drug Administration that encompasses both its revolutionary hepatic Chemosat therapy device that delivers chemotherapy agents directly to the liver via hepatic artery infusion, as well as the cancer-fighting agent it purchased from GlaxoSmithKline (NYSE: GSK ) in 2003, melphalan."

    Sentiment: Buy

  • Reply to

    future is not easy

    by samnotsamuel1 Nov 21, 2014 9:45 AM
    melikesdinero melikesdinero Nov 21, 2014 10:44 AM Flag

    The future is more promising than the past 24 years =)

    Sentiment: Buy

  • Reply to

    DCTH - any near-term catalysts?

    by kei.trader Nov 11, 2014 10:49 PM
    melikesdinero melikesdinero Nov 19, 2014 2:34 PM Flag

    Akon Stops Bashing =) Nice post Sam.

    Sentiment: Buy

  • Reply to

    fundamentals vs. insider buys

    by samnotsamuel1 Nov 7, 2014 11:26 AM
    melikesdinero melikesdinero Nov 7, 2014 3:17 PM Flag

    Good man. Happy to see you having some fun. Hope you make some $$. This flies or dies. Place your bets.

    Sentiment: Buy

  • Reply to

    fundamentals vs. insider buys

    by samnotsamuel1 Nov 7, 2014 11:26 AM
    melikesdinero melikesdinero Nov 7, 2014 11:43 AM Flag

    Do you have a job? =)

    Sentiment: Buy

  • Reply to

    A Challenge to Stoll and Simpson

    by who_gnu_1235 Nov 6, 2014 1:44 PM
    melikesdinero melikesdinero Nov 7, 2014 10:10 AM Flag

    They're science focused, obviously not business / marketing focused... I have to agree. What's nice is Germany is picking it up anyway, and the doubling of treatments there isn't insignificant.

    Sentiment: Buy

  • melikesdinero by melikesdinero Nov 5, 2014 1:32 PM Flag

    New German Hospital
    Seems like a new German hospital in Hannover offering Chemosat.

    11/4 Press Release.

    Using google translate:

    Specialists of the Hannover Medical School (MHH) for the first time a new therapy for the treatment of liver tumors have been successfully used in two patients. This is the so-called Chemosaturation. It provides in particular in patients who have no other treatment more responsive the ability to fight the tumor in the liver effective. The minimally invasive method has so far been applied only in a few specialized clinics in Germany.

    When Chemosaturation the physician the liver to flood through the artery with a high-dose chemotherapy. During this procedure, the liver is isolated through a second special catheter from the rest of the blood circulation of the body, the liver blood is passed outside of the body by means of special filters. The purified blood then add the doctors again the bloodstream. Characterized the side-effects of the cytostatic agent is less. Patients can go about their everyday habits after a hospital stay of a few days. The Chemosaturation may be for inoperable malignant liver tumors or metastatic tumors that are confined to the liver, used. These include liver metastasis in colorectal cancer (colon cancer), melanoma (skin cancer) or in uveal melanoma in the eye. Also liver tumors can be treated with their own method.

    At the MHH the complex intervention of an experienced team of hepatologists, oncologists, radiologists, anesthesiologists and perfusionists is performed. "We are very pleased that the medical team with the Chemosaturation can complement the range of minimally invasive local treatment of tumors in the liver and hope for us from a further appreciation of the MHH as a center of excellence in the treatment of liver tumors," says Professor Dr. Michael Peter Manns , director of the MHH Clinic for Gastr

    Sentiment: Buy

  • Reply to

    Bottom

    by b85ferraz Nov 4, 2014 10:52 AM
    melikesdinero melikesdinero Nov 5, 2014 1:24 PM Flag

    Not pumping here. Buying, Sir.

    Sentiment: Buy

  • Reply to

    Bottom

    by b85ferraz Nov 4, 2014 10:52 AM
    melikesdinero melikesdinero Nov 4, 2014 11:56 AM Flag

    b8 - Have you ever posted here in the last few years? srosone - What are you doing here, if you don't like it? Short and be happy. Or buy and go long. Simple stuff, Bro.

    Sentiment: Buy

  • Reply to

    initial uk experience

    by samnotsamuel1 Nov 3, 2014 8:54 AM
    melikesdinero melikesdinero Nov 3, 2014 10:46 AM Flag

    Says who? Insurance reimbursement upgrade in Germany, pending.

    Sentiment: Buy

  • Reply to

    dinero

    by samnotsamuel1 Oct 30, 2014 4:37 PM
    melikesdinero melikesdinero Oct 31, 2014 5:45 PM Flag

    Minor relevance in the EU.

    Sentiment: Buy

  • Reply to

    dinero

    by samnotsamuel1 Oct 30, 2014 4:37 PM
    melikesdinero melikesdinero Oct 31, 2014 2:37 PM Flag

    You must have come up with a better replacement technology for this cancer treatment nitch. Good luck with that.

    Sentiment: Buy

  • Reply to

    Still Buying German DCTH Here

    by melikesdinero Oct 30, 2014 3:43 PM
    melikesdinero melikesdinero Oct 30, 2014 3:58 PM Flag

    Anyone with minimal exposure to commercial developments / advances knows that a year is a very short amount of time... The events that have taken place in Germany during 2014 are under-rated.

    Sentiment: Buy

  • melikesdinero by melikesdinero Oct 30, 2014 3:43 PM Flag

    There's not a more viable LIver Cancer Solution out there.

    Sentiment: Buy

DCTH
1.35-0.01(-0.74%)Dec 26 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
MALAYSIAN AIRLINE SYSTEM BHD
Kuala Lumpur Stock Exchange Fri, Dec 12, 2014 3:59 AM EST